Yahoo Finance

Praxis Precision Medicines Announces Topline Results from the Essential1 Study of ...

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...
Investing

Praxis study halted for futility, other programs advance

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent (LON:IOG) Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is ...
Nasdaq

Praxis (PRAX) Tanks on Negative Data From Depression Study

Shares of Praxis Precision Medicines, Inc. PRAX were down 78.1% on Monday after the company announced disappointing data from the phase II/III Aria study that evaluated its pipeline candidate, ...
Yahoo Finance

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study ...

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Investing

Praxis Precision shares hold buy rating as study shows promise in epilepsy

On Tuesday, Truist Securities maintained a Buy rating and a $150.00 stock price target for Praxis Precision Medicines Inc. (NASDAQ: PRAX), following the announcement of positive results from their ...
Nasdaq

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of ...

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Investing

Praxis Precision shares target raised, holds buy rating on positive study data

On Wednesday, Needham maintained a Buy rating on shares of Praxis Precision Medicines Inc. (NASDAQ: PRAX) and increased the price target to $151 from $145. The adjustment follows Praxis's recent ...